靶向联合免疫新辅助方案在老年晚期肝细胞癌中的治疗效果及外周嗜酸性粒细胞与血管内皮生长因子水平预后价值评估
CSTR:
作者:
作者单位:

(宜昌市中心人民医院肝胆胰脾外科,湖北 宜昌 444100)

作者简介:

通讯作者:

中图分类号:

基金项目:

湖北省自然科学基金创新发展联合基金(2022AFD188)


Therapeutic effect of targeted therapy combined with immune neoadjuvant regimen on elderly advanced hepatocellular carcinoma and monitoring significance of peripheral eosinophil and vascular endothelial growth factor levels
Author:
Affiliation:

(Department of Hepatobiliary Pancreatic Spleen Surgery, Yichang Central People′s Hospital, Yichang 444100, Hubei Province, China)

Fund Project:

This work was supported by Joint Innovation and Development Project of Hubei Natural Science Foundation(2022AFD188).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 研究靶向联合免疫新辅助方案在治疗老年晚期肝细胞癌(HCC)中的临床价值,并分析治疗过程中监测嗜酸性粒细胞(EOS)与血管内皮生长因子(VEGF)水平的价值。方法 回顾性分析2020年1月至2023年1月宜昌市中心人民医院收治的160例老年晚期HCC患者的临床资料。根据治疗方案将其分为A组(单纯靶向治疗,n=51)、B组(单纯免疫治疗,n=43)、C组(靶向联合免疫治疗,n=66),采用改良实体肿瘤疗效评价标准(mRECIST)评估三组治疗效果;统计三组治疗不良反应;随访至2024年12月,统计三组总生存时间(OS)及疾病无进展生存期(PFS),并分别于治疗前及3个用药周期后,检测患者外周血EOS与血清VEGF水平;绘制受试者工作特征(ROC)曲线,分析治疗前后外周血EOS及血清VEGF水平差值在预测患者病灶控制率(DCR)中的价值。采用SPSS 26.0软件进行数据分析。根据数据类型,组间比较分别采用单方差检验、χ2检验及Fisher确切概率检验。结果 C组客观反应率(ORR)及病灶控制率(DCR)高于A、B两组,差异有统计学意义(P<0.05);A、B两组的ORR及DCR比较,差异无统计学意义(P>0.05)。三组≥Ⅲ级不良反应发生率比较,差异均无统计学意义(P>0.05)。A组OS为10.46个月(95%CI 0.340~9.794),B组为10.88个月(95%CI 0.389~10.115),C组为14.18个月(95%CI 0.323~13.543),其中A、B两组OS比较,差异无统计学意义(Log-rank χ2=l0.446,P=0.504),C组OS长于A、B两组(Log-rank χ2=31.030,P<0.001)。A组PFS为5.06个月(95%CI 0.367~4.432),B组PFS为5.19个月(95%CI 0.361~4.486),C组PFS为6.36个月(95%CI 00.294~5.784),三组PFS比较,差异无统计学意义(Log-rank χ2=3.987,P=0.136)。三组治疗前外周血EOS及血清VEGF水平比较,差异均无统计学意义(P>0.05),经3个用药周期后,三组外周血EOS水平均较治疗前上升(P<0.05),血清VEGF水平均较治疗前下降(P<0.05),且C组经治疗后EOS水平高于A、B组,VEGF水平低于A、B组,治疗前后EOS差值及VEGF差值均高于A、B组,差异均有统计学意义(P<0.05)。最佳治疗前后EOS差值(最佳截断值=1.24,AUC=0.845,95%CI 0.778~0.911,灵敏度0.780,特异度0.845,P<0.001)以及VEGF差值(最佳截断值=49.26,AUC=0.786,95%CI 0.713~0.859,灵敏度0.700,特异度0.755,P<0.001)在预测患者治疗后是否能达到DCR中均具有一定价值,而两者联合的预测价值最高(AUC=0.894,95%CI 0.842~0.947,灵敏度0.920,特异度0.818,P<0.001)。结论 靶向联合免疫治疗能有效提高老年HCC患者治疗效果,延长患者生存时间,且不增加不良反应,患者治疗前及3个用药周期后的外周血EOS及血清VEGF的差值在预测其是否能达到DCR中具有一定价值,可作为老年晚期HCC患者治疗反应性的预测指标。

    Abstract:

    Objective To investigate the clinical value of targeted therapy combined with immune neoadjuvant regimen in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC) and to analyze the value of monitoring eosinophil (EOS) and vascular endothelial growth factor (VEGF) levels during treatment. Methods A retrospective analysis was conducted on 160 elderly patients with advanced HCC admitted to Yichang Central People′s Hospital from January 2020 to January 2023. According to the treatment regimens, the patients were divided into group A (targeted therapy alone, n=51), group B (immunotherapy alone, n=43), and group C (targeted therapy combined with immunotherapy, n=66). The modified response evaluation criteria in solid tumors (mRECIST) was used to evaluate the therapeutic efficacy. The treatment-related adverse events were recorded. The patients were followed until December 2024. The overall survival (OS) and progression-free survival (PFS) were recorded. The levels of peripheral blood EOS and serum VEGF were measured before treatment and after 3 medication cycles. Receiver operating characteristic (ROC) curves were plotted to analyze the value of differences of peripheral blood EOS and serum VEGF levels before and after treatment in predicting the disease control rate (DCR). SPSS 26.0 was used for statistical analysis. Data comparison between two groups was performed using One-way ANOVA, χ2 test or Fisher′s exact probability test depending on data type. Results The objective response rate (ORR) and DCR in group C were significantly higher than those in groups A and B (P<0.05), but there were no statistical differences in ORR and DCR between group A and group B (P>0.05). There were no statistically significant differences in the incidence of ≥ Ⅲ adverse events among the three groups (P>0.05). The OS was 10.46 months (95%CI 0.340-9.794) in group A, 10.88 months (95%CI 0.389-10.115) in group B, and 14.18 months (95%CI 0.323-13.543) in group C , without statistical significance between groups A and B (Log-rank χ2=10.446, P=0.504) and with longer OS in group C than those in groups A and B (Log-rankχ2=31.030, P<0.001). PFS was 5.06 months (95%CI 0.367-4.432) in group A, 5.19 months (95%CI 0.361-4.486) in group B, and 6.36 months (95%CI 0.294-5.784) in group C, without statistically differences among the three groups (Log-rank χ2=3.987, P=0.136). No statistical differences were found in peripheral blood EOS and serum VEGF levels among the three groups before treatment (P>0.05). After 3 medication cycles, the peripheral blood EOS levels in all groups were enhanced as compared with those before treatment (P<0.05), while serum VEGF levels decreased as compared with those before treatment (P<0.05). Moreover, after treatment, group C had higher EOS level and lower VEGF level than groups A and B; Group C had greater difference in EOS and VEGF levels before and after treatment than groups A and B; the differences were statistically significant (P<0.05). EOS difference (best cut-off value=1.24, AUC=0.845,95%CI 0.778-0.911, sensitivity 0.780, specificity 0.845, P<0.001) and VEGF difference (best cut-off value=49.26, AUC=0.786,95%CI 0.713-0.859, sensitivity 0.700, specificity 0.755, P<0.001) before and after treatment had certain value in predicting whether patients would achieve DCR after treatment. The combination of the two had the highest predictive value (AUC=0.894,95%CI 0.842-0.947, sensitivity 0.920, specificity 0.818, P<0.001). Conclusion Targeted therapy combined with immunotherapy can effectively enhance therapeutic efficacy and prolong the survival time in elderly patients with advanced HCC without increasing adverse events. The differences in peripheral blood EOS and serum VEGF levels before treatment and after 3 medication cycles have certain value in predicting whether patients will achieve DCR, and can be used as predictors of treatment response in elderly patients with advanced HCC.

    参考文献
    相似文献
    引证文献
引用本文

陈鹏,鲁光锐.靶向联合免疫新辅助方案在老年晚期肝细胞癌中的治疗效果及外周嗜酸性粒细胞与血管内皮生长因子水平预后价值评估[J].中华老年多器官疾病杂志,2026,25(7):504-510
DOI:10.11915/j. issn.1671-5403.2026.07.103

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-07-04
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-08-05
  • 出版日期:
文章二维码